The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort

Yuya Yokoyama^{¶1}, Yuki Ohta^{¶1}, Sadahisa Ogasawara^{¶1, 2}, Jun Kato*¹, Ryoko Arai¹, Hirotaka Koseki³, Masaya Saito⁴, Tatsuya Kaneko¹, Mamoru Tokunaga¹,

Hirotaka Oura¹, Tsubasa Oike¹, Yushi Imai¹, Kengo Kanayama¹, Naoki Akizue¹,
Junichiro Kumagai¹, Takashi Taida¹, Kenichiro Okimoto¹, Keiko Saito¹,
Yoshihiko Ooka¹, Tomoaki Matsumura¹, Tomoo Nakagawa¹, Makoto Arai^{1, 5},
Tatsuro Katsuno¹, Yoshihiro Fukuda⁴, Yoshio Kitsukawa³, Naoya Kato¹

¹Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan

²Translational Research and Development Center, Chiba University Hospital, Chiba, Japan

 ³Department of Gastroenterology, Chiba Aoba Municipal Hospital, Chiba, Japan
 ⁴Department of Gastroenterology, Seikeikai Chiba medical center, Chiba, Japan
 ⁵Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan

1

Supplementary Figure 1. Transitions of followed up number of patients (A), proportions of worst exacerbations (B), and hospitalization rates (C) per year in patients with ulcerative colitis in the present cohort.

Supplementary Figure 2. Transitions of correlations between age of onset and years in patients with ulcerative colitis in Japan.

Supplementary Figure 3. Transition of treatments used before and in the bio-era.

Supplementary Figure 4. Definition of initial and relapse exacerbations in this cohort.



Suppl. Figure 1 Yokoyama et al.

Suppl. Figure 2 Yokoyama et al.





 $\mathbf{5}$